Dare Bioscience Inc
$ 1.22
-2.40%
22 Jul - close price
- Market Cap 18,724,400 USD
- Current Price $ 1.22
- High / Low $ 1.29 / 1.19
- Stock P/E N/A
- Book Value 0.05
- EPS -0.85
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -25.43 %
- 52 Week High 3.78
- 52 Week Low 1.19
About
Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's health products in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$9.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-26 | 2025-11-13 | 2025-08-14 | 2025-05-13 | 2025-03-31 | 2024-11-14 | 2024-08-12 | 2024-05-14 | 2024-03-28 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.2 | -0.1006 | -0.28 | -0.45 | -0.5 | -0.65 | -0.55 | -0.89 | -0.84 | -0.06 | -1.08 | -1.2 |
| Estimated EPS | -0.3 | -0.42 | -0.4 | -0.58 | -0.58 | -0.6333 | -0.71 | -0.66 | -0.72 | -0.1 | -1.2 | -1.08 |
| Surprise | 0.1 | 0.3194 | 0.12 | 0.13 | 0.08 | -0.0167 | 0.16 | -0.23 | -0.12 | 0.04 | 0.12 | -0.12 |
| Surprise Percentage | 33.3333% | 76.0476% | 30% | 22.4138% | 13.7931% | -2.637% | 22.5352% | -34.8485% | -16.6667% | 40% | 10% | -11.1111% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DARE
2026-07-22 06:42:43
Analysts are optimistic about Daré Bioscience (NASDAQ: DARE), predicting it will reach profitability by 2028 after posting a final loss in 2027. The company's growth is projected to be 66% year-on-year, but investors should consider its high debt-to-equity ratio as a potential risk. Daré Bioscience develops therapies in contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health.
2026-07-21 10:11:53
Daré Bioscience, Inc., a biopharmaceutical company with a US$29m market cap, is reportedly nearing profitability, with analysts predicting breakeven in 2027 and a profit of US$1.3m in 2028. This growth requires an extremely buoyant 66% year-on-year increase. However, the company also carries a significant debt-to-equity ratio of over 2x, which poses an increased risk for investors.
2026-07-20 18:11:53
Daré Bioscience, Inc. has announced a "nationwide virtual bus tour" webinar series to engage investors. President and CEO, Sabrina Martucci Johnson, will host events to discuss the company's commercial strategy, product portfolio, and growth opportunities in women's health. The series includes four regional "stops" with live Q&A sessions and information on their Regulation A offering.
2026-07-20 14:41:05
Daré Bioscience, a biotech company focused on women's health, has initiated a virtual bus tour webinar series to engage investors. Hosted by CEO Sabrina Martucci Johnson, these webinars will provide updates on the company's commercial strategy, product portfolio, and growth opportunities. The series also aims to inform shareholders about Daré's ongoing Regulation A offering and includes live Q&A sessions.
2026-07-20 13:41:05
Daré Bioscience (NASDAQ: DARE) has announced a "Across the U.S." Virtual Bus Tour Webinar Series for investors, aimed at providing direct access to company leadership and insights into its women's health portfolio and commercial strategy. Hosted by CEO Sabrina Martucci Johnson, the series will include corporate presentations and Q&A sessions. This initiative highlights the company's commitment to transparent communication and addressing unmet needs in women's health through innovative solutions.
2026-07-20 12:41:04
Daré Bioscience (NASDAQ: DARE) has launched a "Across the U.S." Virtual Bus Tour Webinar Series to engage investors and showcase its commercial strategy and growth opportunities in women's health. Hosted by CEO Sabrina Martucci Johnson, the series will include corporate updates, discussions on their product portfolio, and interactive Q&A sessions. The company focuses on addressing unmet needs in women's health, from contraception and menopause to sexual and vaginal health, and will also provide information on its ongoing Regulation A offering.
